key: cord-0676282-18ibmy0n
authors: Piplani, Sakshi; Singh, Puneet; Winkler, David A.; Petrovsky, Nikolai
title: Computationally repurposed drugs and natural products against RNA dependent RNA polymerase as potential COVID-19 therapies
date: 2020-11-29
journal: nan
DOI: nan
sha: 4e00dddd6c98ff1d7df1ea941cf061f20128d67b
doc_id: 676282
cord_uid: 18ibmy0n

For fast development of COVID-19, it is only feasible to use drugs (off label use) or approved natural products that are already registered or been assessed for safety in previous human trials. These agents can be quickly assessed in COVID-19 patients, as their safety and pharmacokinetics should already be well understood. Computational methods offer promise for rapidly screening such products for potential SARS-CoV-2 activity by predicting and ranking the affinities of these compounds for specific virus protein targets. The RNA-dependent RNA polymerase (RdRP) is a promising target for SARS-CoV-2 drug development given it has no human homologs making RdRP inhibitors potentially safer, with fewer off-target effects that drugs targeting other viral proteins. We combined robust Vina docking on RdRP with molecular dynamic (MD) simulation of the top 80 identified drug candidates to yield a list of the most promising RdRP inhibitors. Literature reviews revealed that many of the predicted inhibitors had been shown to have activity in in vitro assays or had been predicted by other groups to have activity. The novel hits revealed by our screen can now be conveniently tested for activity in RdRP inhibition assays and if conformed testing for antiviral activity invitro before being tested in human trials

Since December 2019 and the outbreak of a pneumonic disease called COVID-19 caused by a novel coronavirus (SARS-CoV-2) in China, clinicians globally have faced unprecedented challenges in managing the disease caused by this pandemic virus. There has been a massive international research effort to discover effective drugs and vaccines for this and other pathogenic coronaviruses such as SARS and MERS. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] Design of potent new coronavirus drugs is very important for future disease preparedness. However, for COVID-19, it is only feasible to use drugs that are already registered (off label use) or approved natural products that been through at least phase 1 clinical trials for safety assessment. These agents can be used in man quickly, as their safety and pharmacokinetics are well understood.

Computational methods offer considerable promise for rapidly screening such drugs for SARS-Cov-2 activity by predicting their affinities for relevant virus protein targets. Recent papers in prominent journals have reported, for example, the application of computational de novo drug design based on the structures of the SARS-Cov-2 protease. [18] [19] [20] The RNA-dependent RNA polymerase (RdRP) is a promising target for SARS-CoV In pandemics, computational methods can quickly identify candidate drugs for repurposing, where speed is of utmost importance. Here we show how a well validated molecular docking followed by a high throughput molecular dynamics simulation (MDS) drug screening program can screen a large number of drugs and natural products to produce a short list of RdRp-inhibiting drug candidates. MDS calculations were used to predict the optimal binding poses and binding energies for 80 of the top hits from virtual screening on SARS-CoV-2

RdRP. Finally we ranked the top candidates for COVID-19 based on binding affinity and novelty.

There have been many computational studies aiming to predict which existing drugs and natural products may be inhibit the main protease, M pro , of SARS-Cov-2, but fewer studies have studied drugs for targeting the viral RdRP. The computational workflow used to estimate the relative binding affinities of drugs for the RdRP binding pocket are summarized in Figure 3 . The combination of robust Vina docking followed by MDS of the top 80 candidates yields improved performance relative to Vina docking alone. 23 The binding free energies calculated by both computational methods (see Methods) correlated very well (r 2 =0.84) and the free energies calculated by the thermodynamic cycle correlate with the Vina docking scores with r 2 = 0.64. The size of the binding site (area 2920 Å 2 and volume 5335 Å 3 ) tends to select larger ligands, many of which are quite flexible. Binding energy penalties due to ligand entropy are likely to be significant. Hence, substantial correlation between the Vina scores and the binding energies from MMBBSA and thermodynamic cycle are important because these algorithms treat ligand entropy approximately and in different ways. 24 Some have had their in vitro activity against SARS-Cov-2 determined experimentally ( Figure   4 ), further supporting our binding predictions. Two RdRp mutations occurred in the Indian population with prevalence >5% and these were analysed as possible targets for repurposed drugs. Docking using Autodock Vina predicted Elbasvir as the best inhibitor of RdRp in the Indian population, followed by Remdesivir and

Natural products and analogues.

Given the large degree of interest in repurposing antiviral drugs for use in treating COVID-19, natural product hits are of greater interest given their relative novelty. The drug with the strongest binding affinity to RdRP in our study was the natural anti-helminthic product,

Ivermectin. Ivermectin and other avermectins and milbemycins are broad spectrum antiparasitic macrocyclic lactones derived from the bacterium Streptomyces avermitilis.

Ivermectin's mode of action is by enhancing inhibitory neurotransmission by binding to glutamate-gated chloride channels. Ivermectin has been shown to be effective against several Figure 5 summarizes the main interactions between Ivermectin and the binding site of RdRP and the docking pose from the MDS. 45 The activity of digoxin in these assays was substantially better than that of chloroquine or remdesivir. Figure 6 shows the main interactions of digoxin with the RdRP binding site and how the drug binds to the catalytic cavity. The main interactions are also listed in Supplementary Table 2 . Novobiocin was also selected as one of the top five best RdRP binders by Choudhury et al.

using the MoleGro virtual docker software. 51 .

Ergotamine and related ergot alkaloids have been predicted to be high binders to SARS-Cov-2 molecular targets, including the main protease, M pro . 20 There are a few literature reports of its binding to the SARS-Cov-2 RdRP enzyme. 52 There is an in silico predicted SARS-Cov-2 IC50 of 190µM. 53 Figure 9 shows the main interactions between the RdRP active site residues and ergotamine, and also illustrates the binding pose from the MDS. The interactions are also listed in Supplementary Table 2. Wu et al. generated homology models of 18 SARS-Cov-2 viral proteins and two human targets and used structure-based virtual ligand screening to identify potential inhibitors of these targets. 47 They identified a range of drugs and natural products that their computational methods suggested may inhibit the RdRP, including beclabuvir.

Bemcentinib selectively inhibits AXL kinase activity, which blocks viral entry and enhances the antiviral type I interferon response. It has been identified as a potential inhibitor of the SARS-Cov-2 M pro enzyme in many computational studies. 20 We indinavir inhibits SARS-Cov-2 with an EC50 >10 µM and CC50 >50 µM (A549-hACE2 cells) 59 and an EC50 of 59 μM and CC50 >81 μM in Vero cells. 60 Again, this high validation success rate reinforced the view that our virtual screening protocols were able to identify existing drugs and approved natural products, for rapid testing in the clinic against COVID-19. The hits may also have activity against other coronaviruses.

The identified drugs may be useful for treating COVID-19 patients and provide a rational computational basis for repurposing drugs for future pandemics and other diseases.

The crystal structure of the SARS-CoV-2 RdRp (Figure 11 ) was downloaded from RCSB PDB (https://www.rcsb.org/structure/6M71) with a reported resolution of 2.90Å. Protein preparation, removal of non-essential and non-bridging water molecules, addition of hydrogen atoms and missing residues and loops for docking studies were performed using UCSF Chimera package (https://www.cgl.ucsf.edu/chimera/). 75 AutoDock Tools (ADT) software was used to prepare the required files for Autodock Vina by assigning hydrogen polarities, calculating Gasteiger charges to protein structures and converting protein structures from the .pdb file format to .pdbqt format. 76 . A total of fifty top compounds selected from each of the Drugbank and CHEMBL compounds.

Fifteen compounds were common to both database top hits. Molecular dynamics studies were conducted on the unique set of eighty-five compounds from both sets.

The top screened compound complexes with protease were minimized with CHARMm force field. The topology files of the ligands were prepared from Swissparam (http://www.swissparam.ch/) 78 and minimized in Gromacs2020 (http://www.gromacs.org/). 79 .

Docked complexes of ligands and COVID-19 M pro protein were used as starting geometries for MD simulations. Simulations were carried out using the GPU accelerated version of the program with the CHARMm force field I periodic boundary conditions in ORACLE server.

Docked complexes were immersed in a truncated octahedron box of TIP3P water molecules.

The solvated box was further neutralized with Na+ or Cl− counter ions using the tleap program.

Particle Mesh Ewald (PME) was employed to calculate the long-range electrostatic interactions. The cut-off distance for the long-range van der Waals (VDW) energy term was 12.0 Å. The whole system was minimized without any restraint. The above steps applied 2500 cycles of steepest descent minimization followed by 5000 cycles of conjugate gradient minimization. After system optimization, the MD simulations was initiated by gradually Calculations were also performed for up to 100 ns on few compounds to ensure that 20ns is sufficiently long for convergence. Duplicate production runs starting with different random seeds were also run to allow estimates of binding energy uncertainties to be determined.

The binding free energies of the protein-protein complexes were evaluated in two ways.

The traditional method is to calculate the energies of solvated SARS-Cov-2 protease and small molecule ligands and that of the bound complex and derive the binding energy by subtraction.

ΔG (binding, aq) = ΔG (complex, aq) -(ΔG (protein, aq) + ΔG (ligand, aq)

We also calculated binding energies using the molecular mechanics Poisson Boltzmann surface area (MM/PBSA) tool in GROMACS that is derived from the nonbonded interaction energies of the complex. The method is also widely used method for binding free energy calculations. where ΔG (R:L,solv), ΔG (R,solv) and ΔG (L,solv) are solvation free energies of complex, receptor and ligand, respectively.

As we noted in a previous SARS-Cov-2 drug repurposing paper targeting the main protease, 20

Guterres and Im showed how substantial improvement in protein-ligand docking results could be achieved using high-throughput MD simulations. 23 for p in part:

Vaccine Development against SARS-CoV-2. Vaccines

COVID-19: a fast evolving pandemic

The COVID-19 vaccine development landscape

World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19)

Repurposing antimalarials and other drugs for COVID-19

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review

What Does Plant-Based Vaccine Technology Offer to the Fight against COVID-19? Vaccines

Perspectives: Potential Therapeutic Options for SARS-CoV-2 Patients Based on Feline Infectious Peritonitis Strategies: Central Nervous System Invasion and Drug Coverage

Research towards treating COVID-19

Timely development of vaccines against SARS-CoV-2

Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees

COVID-19 needs a big science approach

CoV-2 agents from commercially available flavor via docking screening. 2020, OSF Preprints osf.io/vjch2

Clinical trials for the treatment of Coronavirus disease 2019 (COVID-19): A rapid response to urgent need

Antiviral Treatment of Covid-19. Turk

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors

Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review)

Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19

Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis

Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2

In Silico Identification of a Potent Arsenic Based Approved Drug Darinaparsin against SARS-CoV-2: Inhibitor of RNA

RdRp) and Essential Proteases. Infect. Disord. Drug Targ. 2020

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir

Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells

Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43

Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19

Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 in vitro infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 <em>in vitro</em>

FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro

Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2

Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19

Vitro Activity of Itraconazole Against SARS-CoV-2. bioRxiv 2020, 2020.11.13.381194 72. Ghahremanpour

Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2

The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells

A Case of Coronavirus Disease 2019 Treated With Ciclesonide

UCSF Chimera--a visualization system for exploratory research and analysis

Computational protein-ligand docking and virtual drug screening with the AutoDock suite

LigPlot+: multiple ligand-protein interaction diagrams for drug discovery

SwissParam: a fast force field generation tool for small organic molecules

High performance molecular simulations through multi-level parallelism from laptops to supercomputers

Predicting inhibitors for SARS-CoV-2 RNAdependent RNA polymerase using machine learning and virtual screening}

Computational screening of repurposed drugs and natural products against SARS-Cov-2 main protease as potential COVID-19 therapies

Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen

Antiviral treatment of COVID-19. Turk

In Vitro Data of Current Therapies for SARS-CoV-2

Evaluation of 19 antiviral drugs against SARS-CoV-2 Infection

Drug repurposing screens reveal FDA approved drugs active against SARS-Cov-2

Covid-19: Remdesivir has little or no impact on survival, WHO trial shows

Tackling COVID-19 Using Remdesivir and Favipiravir as Therapeutic Options

In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2

Comparative analysis of antiviral efficacy of FDAapproved drugs against SARS-CoV-2 in human lung cells

Remdesivir Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA

Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS

CoV-2 RNA dependent RNA polymerase (RdRp): A molecular docking study

Evaluating the potential of different inhibitors on RNA-dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2: A molecular modeling approach

Penciclovir and Anidulafungin bind nsp12, which governs the RNA-dependent-RNA polymerase activity of SARS-CoV-2, with higher interaction energy than Remdesivir, indicating potential in the treatment of Covid-19 infection

Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19

Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients

Potential Treatment of Chinese and Western Medicine Targeting Nsp14 of SARS-CoV-2

COVID-19: Drug Targets and Potential Treatments

Discovery of New Hydroxyethylamine Analogs against 3CLpro Protein Target of SARS-CoV-2: Molecular Docking, Molecular Dynamics Simulation, and Structure-Activity Relationship Studies

Targeting the 3CLpro and RdRp of SARS-CoV-2 with phytochemicals from medicinal plants of the Andean Region: molecular docking and molecular dynamics simulations

A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19

Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach

Repurposing of FDA Approved Drugs for the Identification of Potential Inhibitors of SARS-CoV-2 Main Protease

In silico studies on therapeutic agents for COVID-19: Drug repurposing approach

Predicting inhibitors for SARS-CoV-2 RNA-dependent RNA polymerase using machine learning and virtual screening

Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV

In silico Repositioning for Dual Inhibitor Discovery of SARS-CoV-2 (COVID-19) 3C-like Protease and Papain-like Peptidase

Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review)

An Update on Current Therapeutic Drugs Treating COVID-19

Data-driven Drug Repurposing for COVID-19. ChemRxiv chemrxiv.12661103.v1 33. Pokhrel, R.; Chapagain, P.; Siltberg-Liberles

polymerase inhibitors as prospective therapeutics against SARS-CoV-2

RdRp) -A drug repurposing study. Heliyon 2020

Identification of Atovaquone, Ouabain and Mebendazole as FDA Approved Drugs Targeting SARS-CoV-2. ChemRxiv 2020, /chemrxiv.12003930.v4 36

Computational guided drug repurposing for targeting 2'-O-ribose methyltransferase of SARS-CoV-2

Identification of Potential Inhibitors of SARS-COV-2 Endoribonuclease (EndoU) from FDA Approved Drugs: A Drug Repurposing Approach to find Therapeutics for COID19

In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNAdependent RNA polymerase inhibitors for direct use in clinical trials

SARS-CoV-2 and SARS-CoV: Virtual screening of potential inhibitors targeting RNA-dependent RNA polymerase activity (NSP12)

Beclabuvir can Inhibit the RNA-dependent RNA Polymerase of Newly Emerged Novel Coronavirus (SARS-CoV-2)

Silico Molecular Dynamics Docking of Drugs to the Inhibitory Active Site of SARS-CoV-2 Protease and Their Predicted Toxicology and ADME

SARS-CoV-2: recent reports on antiviral therapies based on lopinavir/ritonavir, darunavir/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus

Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

State-of-the-art tools unveil potent drug targets amongst clinically approved drugs to inhibit helicase in SARS-CoV-2

Drug Repurposing for Candidate SARS-CoV-2 Main Protease Inhibitors by a Novel in Silico Method

Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data

A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease

Plant-derived natural polyphenols as potential antiviral drugs against SARS-CoV-2 via RNA-dependent RNA polymerase (RdRp) inhibition: an in-silico analysis

An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study

Discovery of potential multi-target-directed ligands by targeting host-specific SARS-CoV-2 structurally conserved main protease

Novel Coronavirus Protease Identified by Virtual Screening of 606 Million Compounds

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro

Simeprevir suppresses SARS-CoV-2 replication and synergizes with remdesivir

Investigating the binding affinity, interaction, and structure-activity-relationship of 76 prescription antiviral drugs targeting RdRp and Mpro of SARS-CoV-2

Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs

Combined in silico docking and in vitro antiviral testing for drug repurposing identified lurasidone and elbasvir as SARS-CoV-2 and HCoV-OC43 inhibitors

Anti-HIV and Anti-HCV drugs are the putative inhibitors of RNAdependent-RNA polymerase activity of NSP12 of the SARS CoV-2 (COVID-19)

3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Combined Deep Learning and Molecular Docking Simulations Approach Identifies Potentially Effective FDA Approved Drugs for Repurposing Against SARS-CoV-2

Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug

Repurposing Against COVID-19: An in silico

Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach

Potential inhibitors of SARS-cov-2 RNA dependent RNA polymerase protein: molecular docking, molecular dynamics simulations and MM-PBSA analyses

Telmisartan as tentative angiotensin receptor blocker therapeutic for COVID-19

Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors

Quantitative Structure-Activity Relationship Machine Learning Models and their Applications for Identifying Viral 3CLpro-and RdRp-Targeting Compounds as Potential Therapeutics for COVID-19 and Related Viral Infections

Discovery of clinically approved drugs capable of inhibiting SARS-CoV-2 <em>in vitro</em> infection using a phenotypic screening strategy and network-analysis to predict their potential to treat covid-19

Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2

In silico identification of potent FDA approved drugs against Coronavirus COVID-19 main protease: A drug repurposing approach

FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 <em>in vitro</em>

Combining SARS-cov-2 Proofreading Exonuclease and RNA-dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: A Highthroughput in Silico Screen

Identification of potent and safe antiviral therapeutic candidates against SARS-CoV-2. bioRxiv 2020

Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19

Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach

Predictive modeling by deep learning, virtual screening and molecular dynamics study of natural compounds against SARS-CoV-2 main protease

Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19

Repurposing of known anti-virals as potential inhibitors for SARS-CoV-2 main protease using molecular docking analysis

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2'-O-ribose methyltransferase of SARS-CoV-2 coronavirus

Repurposing Therapeutics to Identify Novel Inhibitors Targeting 2'-O-Ribose Methyltransferase Nsp16 of SARS-CoV-2

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2

An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors

Flavonoid glycosides and their putative human metabolites as potential inhibitors of the SARS-CoV-2 main protease (Mpro) and RNAdependent RNA polymerase (RdRp)

Silico Drug Repurposing for SARS-CoV-2 Main Proteinase and Spike Proteins

In-silico analysis of potential interaction of drugs and the SARS-CoV-2 spike protein

Potential drugs targeting Nsp16 protein may corroborates a promising approach to combat SARS-CoV-2 virus

COVID-19 and Flavonoids: In Silico Molecular Dynamics Docking to the

Active Catalytic Site of SARS-CoV and SARS-CoV-2 Main Protease

Virtual Screening of Inhibitors Against Spike Glycoprotein of SARS-CoV-2: A Drug Repurposing Approach

Drugs repurposing for coronavirus treatment: Computational study based on molecular topology

Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking Screening

Comparative docking of SARS-CoV-2 receptors antagonists from repurposing drugs

Tropsha, A. QSAR Modeling of SARS-CoV M(pro)Inhibitors Identifies

Proglumetacin, and Other Drugs as Candidates for Repurposing against SARS-CoV-2. Mol

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19

COVID-19) through Computational Drug Repurposing Study

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Discovery of COVID-19 Inhibitors Targeting the SARS-CoV-2 Nsp13 Helicase

Stimulating open drug discovery for SARS-CoV

Computational View toward the Inhibition of SARS-CoV-2 Spike Glycoprotein and the 3CL Protease

The inhaled steroid ciclesonide blocks SARS-CoV-2 RNA replication by targeting the viral replication-transcription complex in cultured cells

A Case of Coronavirus Disease 2019 Treated With Ciclesonide

Computational Drug Repurposing Studies on SARS-CoV-2 Protein Targets

We would also like to thank Oracle for providing their Cloud computing resources for the